What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Oncology, Cancer, Pharmacology and Surgery.
As part of his studies on Internal medicine, he often connects relevant subjects like Gastroenterology.
The study incorporates disciplines such as Clinical endpoint, Clinical trial, Metastatic breast cancer, Placebo and Metastasis in addition to Oncology.
His Trastuzumab study in the realm of Cancer connects with subjects such as Fibroblast growth factor receptor 1.
Howard A. Burris has included themes like Protein kinase B and Phosphatidylinositol in his Pharmacology study.
His Surgery research focuses on Carcinoma and how it connects with Paclitaxel.
His most cited work include:
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial (1967 citations)
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (1957 citations)
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (1641 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Oncology, Pharmacology, Pharmacokinetics and Cancer.
His Internal medicine research incorporates themes from Gastroenterology and Surgery.
His Surgery research is multidisciplinary, relying on both Lung cancer and Carcinoma.
Taxane is closely connected to Trastuzumab in his research, which is encompassed under the umbrella topic of Oncology.
His Pharmacokinetics research is multidisciplinary, incorporating elements of Rash and Dosing.
His Cancer study integrates concerns from other disciplines, such as Placebo, Gynecology and Clinical trial, Pathology.
He most often published in these fields:
- Internal medicine (63.90%)
- Oncology (46.99%)
- Pharmacology (25.85%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (63.90%)
- Oncology (46.99%)
- In patient (19.02%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, In patient, Cancer and Cancer research.
Internal medicine is often connected to Gastroenterology in his work.
The Gastroenterology study which covers Toxicity that intersects with Metastatic Urothelial Carcinoma.
The concepts of his Oncology study are interwoven with issues in Clinical endpoint, Clinical trial, Carboplatin, Metastatic breast cancer and Placebo.
His Cancer study also includes
- MEDLINE together with Position,
- Phases of clinical research which connect with Everolimus and Exemestane.
His work on Glioma as part of general Cancer research research is frequently linked to Phase, thereby connecting diverse disciplines of science.
Between 2017 and 2021, his most popular works were:
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (198 citations)
- Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study (165 citations)
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study (143 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Howard A. Burris focuses on Internal medicine, Oncology, Cancer, Adverse effect and Cancer research.
His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology.
The Oncology study combines topics in areas such as Multicenter study, Pertuzumab, Metastatic breast cancer, Placebo and Clinical endpoint.
His biological study spans a wide range of topics, including Immunohistochemistry and Antibody.
His Adverse effect research includes themes of Carcinoma, Progression-free survival and Evaluable Disease.
His study in the fields of Glioma under the domain of Cancer research overlaps with other disciplines such as In patient and Isocitrate dehydrogenase.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
